Drug intelligence / Profile preview

rosmantuzumab

Development stage: Phase 1
Lead developer: Mereo BioPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody that targets R-spondin 3 (RSPO3), a protein involved in the modulation of the Wnt/β-catenin signaling pathway. By binding to RSPO3, rosmantuzumab inhibits its interaction with leucine-rich repeat-containing G-protein coupled receptors (LGR4, LGR5, and LGR6), thereby blocking activation of the RSPO-LGR pathway and curtailing aberrant Wnt/β-catenin signaling. This mechanism is implicated in various cancers and fibrotic diseases. Rosmantuzumab was developed by OncoMed Pharmaceuticals and has been investigated primarily for advanced solid tumors, including colorectal cancer[1][3][5][8].

Brand names: rosmantuzumab
Other names: rosmantuzumabOMP-131R10OMP131R10OMP 131R10

Targets

RSPO3 (R-spondin 3)

Beyond the preview

Go deeper on rosmantuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rosmantuzumab.

Explore the full profile